Overview

The purpose of the research is to determine whether a medication called dapagliflozin will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking the medication dapagliflozin (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months.

Eligibility

Inclusion Criteria:

• Patients with their first STEMI (> 18 years and < 75 years) who underwent successful primary PCI and able to give informed consent
• At least mild LV dysfunction (LVEF < 50%) on echocardiogram, cMRI or Left Ventriculargram following PCI
• Infarct size that is > 10% of LV mass
• The presence of MVO that is > 10% of infarct size

Exclusion Criteria:

• Contraindication to cardiac MRI
• Life expectancy < 1 year
• Previous CABG or Valve Surgery
• Previous STEMI
• Pregnant or planning to become pregnant or lactating women
• Cardiogenic shock (not resolved)
• Atrial fibrillation or recurrent sustained ventricular arrhythmias (excluding PVCs)
• GFR<30 ml/min/1.73m2 or end-stage renal disease on dialysis
• Type 1 diabetes mellitus or history of diabetic ketoacidosis
• Type I or II diabetes with insulin use
• Prior intolerance of SGLT2 inhibitors
• Current use of SGLT2 inhibitors
• Contraindications to gadolinium